Hepion Pharmaceuticals Announces Reverse Stock Split
Hepion Pharmaceuticals (NASDAQ: HEPA) has announced a 1-for-50 reverse stock split, effective March 17, 2025, at 4:01 p.m. Eastern Time. The company's shares will begin trading on a split-adjusted basis on March 18, 2025, maintaining its NASDAQ symbol 'HEPA' with a new CUSIP number 426897 401.
The reverse split aims to increase the bid price to meet NASDAQ's $1.00 minimum bid requirement for continued listing. This corporate action will reduce outstanding shares from approximately 54.25 million to 1.08 million. Stockholders approved this measure at the annual meeting on March 10, 2025.
The split will automatically combine every 50 shares into one share, with fractional shares rounded up to the next whole share. This action will not affect stockholders' ownership percentages or voting power, except for minimal changes due to fractional share treatment. Proportionate adjustments will be made to stock options, incentive plans, and outstanding warrants.
Hepion Pharmaceuticals (NASDAQ: HEPA) ha annunciato un frazionamento inverso delle azioni 1-per-50, che entrerà in vigore il 17 marzo 2025 alle 16:01 ora orientale. Le azioni della società inizieranno a essere negoziate sulla base del frazionamento il 18 marzo 2025, mantenendo il simbolo NASDAQ 'HEPA' con un nuovo numero CUSIP 426897 401.
Il frazionamento inverso mira ad aumentare il prezzo di offerta per soddisfare il requisito minimo di offerta di $1.00 di NASDAQ per la continua quotazione. Questa azione aziendale ridurrà le azioni in circolazione da circa 54,25 milioni a 1,08 milioni. Gli azionisti hanno approvato questa misura durante l'assemblea annuale del 10 marzo 2025.
Il frazionamento combinerà automaticamente ogni 50 azioni in un'azione, con le azioni frazionarie arrotondate all'azione intera successiva. Questa azione non influirà sulle percentuali di proprietà o sul potere di voto degli azionisti, ad eccezione di lievi variazioni dovute al trattamento delle azioni frazionarie. Verranno effettuati aggiustamenti proporzionali per le opzioni azionarie, i piani di incentivazione e i warrant in circolazione.
Hepion Pharmaceuticals (NASDAQ: HEPA) ha anunciado un desdoblamiento inverso de acciones 1-por-50, que entrará en vigor el 17 de marzo de 2025 a las 4:01 p.m. hora del Este. Las acciones de la compañía comenzarán a negociarse en base al desdoblamiento el 18 de marzo de 2025, manteniendo su símbolo NASDAQ 'HEPA' con un nuevo número CUSIP 426897 401.
El desdoblamiento inverso tiene como objetivo aumentar el precio de oferta para cumplir con el requisito mínimo de oferta de $1.00 de NASDAQ para la cotización continua. Esta acción corporativa reducirá las acciones en circulación de aproximadamente 54,25 millones a 1,08 millones. Los accionistas aprobaron esta medida en la reunión anual del 10 de marzo de 2025.
El desdoblamiento combinará automáticamente cada 50 acciones en una acción, con acciones fraccionarias redondeadas a la siguiente acción completa. Esta acción no afectará los porcentajes de propiedad de los accionistas ni su poder de voto, excepto por cambios mínimos debido al tratamiento de acciones fraccionarias. Se realizarán ajustes proporcionales a las opciones sobre acciones, planes de incentivos y warrants en circulación.
헤피온 제약 (NASDAQ: HEPA)는 2025년 3월 17일 동부 표준시 오후 4시 1분에 1대 50의 액면 분할을 발표했습니다. 회사의 주식은 2025년 3월 18일부터 분할 조정 기준으로 거래를 시작하며, NASDAQ 기호 'HEPA'를 유지하고 새로운 CUSIP 번호 426897 401로 변경됩니다.
이 액면 분할의 목적은 NASDAQ의 지속적인 상장을 위한 최소 입찰 요건인 $1.00에 맞추기 위해 입찰가를 높이는 것입니다. 이 기업 행동은 발행 주식을 약 5425만 주에서 108만 주로 줄이는 효과가 있습니다. 주주들은 2025년 3월 10일 연례 회의에서 이 조치를 승인했습니다.
이 분할은 자동으로 50주를 1주로 결합하며, 분할 주식은 다음 전체 주식으로 반올림됩니다. 이 조치는 주주의 소유 비율이나 투표 권한에 영향을 미치지 않지만, 분할 주식 처리로 인한 최소한의 변화가 있을 수 있습니다. 주식 옵션, 인센티브 계획 및 발행된 워런트에 비례 조정이 이루어질 것입니다.
Hepion Pharmaceuticals (NASDAQ: HEPA) a annoncé un regroupement d'actions inversé de 1 pour 50, effectif le 17 mars 2025 à 16h01, heure de l'Est. Les actions de la société commenceront à être négociées sur une base ajustée au regroupement le 18 mars 2025, conservant son symbole NASDAQ 'HEPA' avec un nouveau numéro CUSIP 426897 401.
Ce regroupement vise à augmenter le prix de l'offre afin de respecter l'exigence minimale de 1,00 $ de NASDAQ pour le maintien de la cotation. Cette action d'entreprise réduira le nombre d'actions en circulation d'environ 54,25 millions à 1,08 million. Les actionnaires ont approuvé cette mesure lors de l'assemblée annuelle du 10 mars 2025.
Le regroupement combinera automatiquement chaque 50 actions en une action, les actions fractionnaires étant arrondies à l'action entière suivante. Cette action n'affectera pas les pourcentages de propriété ou le pouvoir de vote des actionnaires, sauf pour des changements minimes dus au traitement des actions fractionnaires. Des ajustements proportionnels seront effectués pour les options d'achat d'actions, les plans d'incitation et les bons de souscription en circulation.
Hepion Pharmaceuticals (NASDAQ: HEPA) hat einen 1-zu-50-Rücksplit der Aktien angekündigt, der am 17. März 2025 um 16:01 Uhr Eastern Time in Kraft tritt. Die Aktien des Unternehmens werden ab dem 18. März 2025 auf einer split-adjustierten Basis gehandelt und behalten das NASDAQ-Symbol 'HEPA' mit einer neuen CUSIP-Nummer 426897 401.
Der Rücksplit zielt darauf ab, den Angebotspreis zu erhöhen, um die Mindestanforderung von $1,00 von NASDAQ für die weitere Notierung zu erfüllen. Diese Unternehmensmaßnahme wird die ausstehenden Aktien von etwa 54,25 Millionen auf 1,08 Millionen reduzieren. Die Aktionäre haben diese Maßnahme auf der Jahreshauptversammlung am 10. März 2025 genehmigt.
Der Split wird automatisch jede 50 Aktien in eine Aktie kombinieren, wobei Bruchstücke auf die nächste volle Aktie aufgerundet werden. Diese Maßnahme hat keine Auswirkungen auf die Eigentumsanteile oder die Stimmrechte der Aktionäre, abgesehen von minimalen Änderungen aufgrund der Behandlung von Bruchstücken. Proportionale Anpassungen werden für Aktienoptionen, Anreizpläne und ausstehende Warrants vorgenommen.
- Potential compliance with NASDAQ listing requirements through bid price increase
- No change in stockholders' proportional ownership or voting rights
- Automatic rounding up of fractional shares benefits small stockholders
- Risk of delisting from NASDAQ if minimum bid price requirement isn't met despite reverse split
- Significant reduction in total outstanding shares may impact stock liquidity
- Indicates underlying share price weakness requiring corporate action
Insights
Hepion Pharmaceuticals' announced 1-for-50 reverse split represents a significant defensive financial maneuver aimed at regaining Nasdaq compliance. With shares trading at just
The extreme ratio of this reverse split is particularly concerning. Most companies implement more modest splits (1-for-5 or 1-for-10), making this 1-for-50 consolidation an indicator of severe underlying financial stress. The mathematics are straightforward: the post-split price should theoretically reach
However, history shows that companies implementing such dramatic splits typically experience continued downward pressure on their share price. The reduction from 54.25 million to approximately 1.08 million shares doesn't alter Hepion's tiny
For existing shareholders, while ownership percentages technically remain unchanged, the psychological impact and market perception of such desperate measures often trigger additional selling pressure. The float post-split will likely result in increased volatility and wider bid-ask spreads, creating additional challenges for investors. This extreme corporate action suggests Hepion faces fundamental financial constraints that may impact its ability to advance its clinical programs.
Shares Expected to Begin Trading on Split-Adjusted Basis on March 18, 2025
MORRISTOWN, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today announced that it will implement a 1-for-50 reverse split of the issued shares of its common stock, effective at 4:01 p.m. Eastern Time on March 17, 2025. The Company's common stock is expected to begin trading on a split-adjusted basis when the market opens on March 18, 2025, and will continue to trade on The Nasdaq Capital Market under the symbol “HEPA.” The new CUSIP number for the common stock will be 426897 401.
The reverse stock split is intended to increase the bid price of the common stock to enable the Company to regain compliance with the
When the reverse stock split becomes effective, every 50 shares of the Company’s common stock issued and outstanding or held by the Company in treasury will automatically be combined and reclassified into one share of common stock. No fractional shares will be issued as a result of the reverse stock split. Stockholders who would otherwise be entitled to receive a fractional share will instead automatically have their fractional interests rounded up to the next whole share, after aggregating all the fractional interests of a holder resulting from the reverse stock split. The reverse stock split will affect all stockholders uniformly and will not change any stockholder’s percentage ownership interest or any stockholder’s proportionate voting power, except for immaterial changes that may result from the treatment of fractional shares. The reverse stock split will not change the number of authorized shares of the Company’s common stock or the par value per share of the Company’s common stock.
The reverse stock split will reduce the number of issued and outstanding shares of the Company’s common stock from approximately 54.25 million to approximately 1.08 million.
As a result of the reverse stock split, proportionate adjustments will be made to the per share exercise prices of, and the number of shares underlying, the Company’s outstanding stock options, as well as to the number of shares available for future awards granted under the Company’s stock incentive plans. In addition, proportionate adjustments will be made to the per share exercise prices of, and the number of shares underlying, outstanding warrants to purchase shares of the Company’s common stock.
The combination of, and reduction in, the issued shares of common stock as a result of the reverse stock split will occur automatically at the effective time of the reverse stock split without any additional action on the part of the Company’s stockholders. The Company's transfer agent, Pacific Stock Transfer Company, is acting as the exchange agent for the reverse stock split and will send stockholders of record holding their shares electronically in book-entry form a transaction notice indicating the number of shares of common stock held after the reverse stock split. Stockholders who hold their shares through a broker, bank, or other nominee will have their positions adjusted to reflect the reverse stock split, subject to their broker, bank, or other nominee’s particular processes, and are not expected to be required to take any action in connection with the reverse stock split.
Additional information regarding the reverse stock split can be found in the Company’s definitive proxy statement for the annual meeting of stockholders of the Company held on March 10, 2025, which was filed with the U.S. Securities and Exchange Commission on February 7, 2025, a copy of which is available at www.sec.gov and on the Company's website.
About Hepion Pharmaceuticals
Hepion’s primary asset, Rencofilstat, is a potent inhibitor of cyclophilins, which are involved in many disease processes. Rencofilstat has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental disease models. In November 2021, the U.S. Food and Drug Administration (“FDA”) granted Fast Track designation for rencofilstat for the treatment of NASH. That was followed in June 2022 by the FDA’s granting of Orphan Drug designation to rencofilstat for the treatment of HCC.
In April 2024, Hepion announced that it was winding down its ASCEND-NASH clinical trial. This trial was designed as a Phase 2b, randomized, multi-center, double-blinded study with first patient screened in August 2022, to evaluate the safety and efficacy of Rencofilstat dosed for 12 months, with a target enrollment of 336 subjects. Enrollment was paused in April 2023, with 151 subjects randomized. To date, approximately 80 subjects have completed their Day 365 visits and are evaluable for both safety and efficacy. An additional 40 subjects will provide significant safety data for evaluation. These patients will be added to Hepion’s existing safety database.
Forward-Looking Statements
The Company cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” “project,” “target,” “objective,” or the negative version of these words and similar expressions. In this press release, forward-looking statements include, but are not limited to, statements relating to the timing, completion and effect of the reverse stock split and the Company’s ability to regain compliance with Nasdaq’s minimum bid price requirement and continue to have its common stock listed on The Nasdaq Capital Market. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, the risk that Nasdaq may not process the reverse stock split on the expected timeline; the risk that after the reverse stock split the closing bid price of the Company’s common stock is not at least
For further information, please contact:
Hepion Pharmaceuticals
info@hepionpharma.com
